MetaCap

Imunon (IMNN) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Imunon is the larger company by market cap ($3.5 million vs $3.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNN-53.03%XTLB-30.81%
+13%-22%-56%
Oct 7, 20261 yearNov 20, 2026
IMNN-50.42%XTLB-30.81%
+18%-18%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNN versus XTLB key metrics
MetricIMNNXTLB
Share price$0.5355$1.37
Market cap$3.47M$3.37M
1-day change-5.22%-5.84%
EPS (TTM)$-3.31$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$451.00K
Net income (latest FY)$-14.50M$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$4.35$5.64
52-week low$0.50$1.37
Distance from 52-week high-87.69%-75.71%
Analyst consensusstrong_buy—
Avg. price target upside+3074.60%—
Average volume150.49K6.58K
Shares outstanding6.49M2.46M
Employees204
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

IMNN vs XTLB FAQ

Which is bigger, Imunon or XTL Biopharmaceuticals?

Imunon (IMNN) is larger, with a market capitalization of $3.47M compared with $3.37M for XTL Biopharmaceuticals (XTLB).

Are Imunon and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons